Funding profile · Cardiac devices

Corveus Medical

One Form D, filed in 2021 under a name the company no longer uses, accounts for $75,000. Everything else that can be documented is grant money, prize money and accelerator equity.

$75.0KSold of $350,000 offered, the only Form D on record
$255.8KNSF SBIR Phase I award, the largest documented single check
$35.0KFirst prize, Texas A&M New Ventures Competition, 2023
$1.5MSeed round listed as in progress, not closed, July 2026

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Sep to Oct 2021 Offering of options to acquire securities, Rule 506(b) $350,000 offered, $75,000 sold 2, unnamed Form D
2022 Y Combinator Not disclosed Y Combinator Company-stated
By Apr 2023 Pre-seed, cumulative $900,000 Not named Company-stated
Feb 2023 NSF SBIR Phase I, award 2213155 $255,841 National Science Foundation NSF
Jun 2023 Texas A&M New Ventures Competition, first place $35,000 plus a legal services prize TNVC Independent
By Aug 2024 First round, as described by the CEO “just under $1M” Not named Company-stated
Open at Jul 2026 Seed $1,500,000 target None named PitchBook

What the filings show

Caridian Medical, Inc. · Form D · filed Oct 29, 2021

First sale
Sep 23, 2021
Offered
$350,000, options to acquire securities
Sold
$75,000 · $275,000 remaining
Investors
2 · average $37,500
Exemption
Rule 506(b) · no non-accredited investors
Commissions
$0 sales commissions, $0 finders fees
Related persons
Tyler Melton (executive officer, director); Ishan Kamat (executive officer, director)
Filing
SEC EDGAR, CIK 0001891109

Reading the filings

  1. Two checks, $37,500 each.$75,000 sold to two investors averages $37,500 apiece, and the securities are options to acquire, which is how convertible notes and SAFEs are reported. This is friends, angels or an accelerator standard instrument, not a priced venture round. $275,000 of the $350,000 offered was never reported sold, and no amendment has been filed.
  2. The filing is under a name nobody searches.The issuer is Caridian Medical, Inc. A search of EDGAR for Corveus Medical returns no company and no documents. The same is true of the NSF grant record, where the awardee of record is Caridian and Corveus appears only as the current entity name. Anyone screening this company by its current name sees a blank sheet.
  3. It was filed 36 days after the first sale.Rule 503 gives an issuer 15 days from the first sale. First sale was September 23, 2021; the notice was filed October 29, 2021. Late Form D filings are common among first-time founders and carry no penalty here, but the date is what it is.
  4. Non-dilutive money is almost four times the reported equity.$255,841 from NSF plus $35,000 in competition prize money is $290,841 of documented funding that cost no ownership, against $75,000 of reported securities sales. That ratio is unusual even for a preclinical device company.
  5. The totals do not reconcile, and the SEC record is the smallest of them.Melton said $900,000 in a pre-seed round in April 2023 and “just under $1M” in August 2024. CB Insights lists $760,000 total raised; PitchBook lists $1.5 million across eight investors; one jobs tracker lists $1 million. The SEC accounts for $75,000. A company raising under Section 4(a)(2) files no Form D at all, so the gap is not evidence that no money moved. It does mean the filed record cannot confirm any of these figures.
  6. No investor has taken a board seat on paper.The 2021 filing lists only the two founders as related persons, each as executive officer and director. Nearly five years later no further filing has added anyone. That is consistent with a cap table of notes and accelerator equity rather than a priced round with governance attached.
  7. The seed round has been open a long time.In April 2023 Melton said the company was raising $1.5 million to fund a three to five patient first-in-human study. PitchBook still lists a $1.5 million seed round as in progress, dated July 13, 2026. The ask has not moved in three years, and neither has the milestone it was meant to buy.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance, approval or other authorization on record. Company says the device requires premarket approval. Public record
Clinical No registered trial. No peer-reviewed publication. Preclinical work described but not released. Not found
Revenue None. Pre-revenue by every description found. Company-stated
Headcount Four to six, depending on the tracker and the date. Three named leaders: CEO, CMO, VP of engineering. Aggregator
Validation by others Y Combinator, MedTech Innovator, MassChallenge, Creative Destruction Lab, Fogarty Innovation, Rosenman Institute. Junkosha innovation award 2024. Houston Innovation Awards finalist 2025. Independent
Category risk A sham-controlled randomized trial of splanchnic nerve ablation by another company missed its primary endpoint in 2024. Any investor here is funding a second attempt at a mechanism that has failed once in a controlled setting. Public record

What to watch

  • A Form D under the name Corveus Medical. There has never been one.
  • An amendment to the 2021 filing, or its formal closure.
  • Whether the seed closes at $1.5 million or is resized for a trial that now has to answer REBALANCE-HF.
  • A named institutional investor and a board seat in a filing.
  • An investigational device exemption, which would put a real milestone against the raise.

The Corveus Medical story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Luminate Medical: Shared investor: First Round. A Galway company building wearables that press the blood supply shut around hair follicles and nerves so chemotherapy reaches less of them
  • Promakhos Therapeutics: Shared investor: First Round. A two-person Boston biotech building an oral small molecule meant to switch the innate immune system back on in Crohn’s disease
  • CareMessage: Shared investor: First Round. A 501(c)(3) nonprofit that sends text messages on behalf of the clinics serving America’s poorest patients
  • ZBiotics: Shared investor: First Round. The first genetically engineered probiotic ever sold to consumers, now past 15 million bottles and profitable

Sources

  1. Public recordForm D, Caridian Medical, Inc., CIK 0001891109SEC EDGAR · Oct 29, 2021
  2. Public recordNSF SBIR Phase I award 2213155NSF · Feb 17, 2023
  3. Public recordEDGAR company and full-text searches for Corveus and CaridianSEC · Sep 23, 2026
  4. Public recordREBALANCE-HF randomized clinical trialJAMA Cardiology · Dec 1, 2024
  5. IndependentCorveus Medical Joins Fogarty Innovation to Tackle Heart FailureFogarty Innovation · Aug 2024
  6. IndependentNew Ventures Competition winner working to solve heart diseaseTexas A&M Engineering · Jun 2023
  7. Independent2025 Houston Innovation Awards finalists: Health Tech BusinessInnovationMap · Oct 22, 2025
  8. AggregatorCorveus Medical company profiles, funding and patent entriesCB Insights, PitchBook · Sep 2026
  9. CompanyTyler Melton presents Corveus Medical at LSI USA ’23, transcriptLife Science Intelligence · Apr 2023
  10. CompanyCorveus Medical website, home and team pagesAccessed Sep 23, 2026

Compiled from SEC, NSF and FDA public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Corveus Medical. This page is not an offer to sell or a recommendation to buy any security.